4. Financial assets
Securities
Securities comprise the following:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Company |
|
Number 31.12.2020 |
|
Change |
|
Number 30.06.2021 |
|
Market price in original currency 30.06.2021 |
|
Valuation CHF mn 30.06.2021 |
|
Valuation CHF mn 31.12.2020 |
||
|
Moderna |
|
2 854 963 |
|
(404 963) |
|
2 450 000 |
|
USD |
|
234.98 |
|
532.5 |
|
264.0 |
|
Ionis Pharmaceuticals |
|
8 220 000 |
|
892 973 |
|
9 112 973 |
|
USD |
|
39.89 |
|
336.3 |
|
411.4 |
|
Argenx SE |
|
921 332 |
|
34 206 |
|
955 538 |
|
USD |
|
301.07 |
|
266.1 |
|
239.8 |
|
Neurocrine Biosciences |
|
3 035 000 |
|
(119 600) |
|
2 915 400 |
|
USD |
|
97.32 |
|
262.4 |
|
257.5 |
|
Incyte |
|
2 900 000 |
|
(3 000) |
|
2 897 000 |
|
USD |
|
84.13 |
|
225.4 |
|
223.3 |
|
Agios Pharmaceuticals |
|
4 158 902 |
|
146 090 |
|
4 304 992 |
|
USD |
|
55.11 |
|
219.5 |
|
159.5 |
|
Fate Therapeutics |
|
2 030 000 |
|
516 336 |
|
2 546 336 |
|
USD |
|
86.79 |
|
204.4 |
|
163.4 |
|
Vertex Pharmaceuticals |
|
900 000 |
|
150 000 |
|
1 050 000 |
|
USD |
|
201.63 |
|
195.8 |
|
188.3 |
|
Alnylam Pharmaceuticals |
|
1 155 000 |
|
(45 000) |
|
1 110 000 |
|
USD |
|
169.52 |
|
174.1 |
|
132.9 |
|
Biogen |
|
537 000 |
|
(37 000) |
|
500 000 |
|
USD |
|
346.27 |
|
160.1 |
|
116.4 |
|
Macrogenics |
|
4 815 564 |
|
1 460 000 |
|
6 275 564 |
|
USD |
|
26.86 |
|
155.9 |
|
97.4 |
|
Arvinas |
|
2 176 903 |
|
– |
|
2 176 903 |
|
USD |
|
77.00 |
|
155.0 |
|
163.7 |
|
Crispr Therapeutics |
|
900 884 |
|
48 700 |
|
949 584 |
|
USD |
|
161.89 |
|
142.2 |
|
122.1 |
|
Intra-Cellular Therapies |
|
3 538 419 |
|
(50 000) |
|
3 488 419 |
|
USD |
|
40.82 |
|
131.7 |
|
99.6 |
|
Radius Health |
|
7 455 714 |
|
– |
|
7 455 714 |
|
USD |
|
18.24 |
|
125.8 |
|
117.9 |
|
Sage Therapeutics |
|
1 540 104 |
|
785 000 |
|
2 325 104 |
|
USD |
|
56.81 |
|
122.2 |
|
117.9 |
|
Myovant Sciences |
|
4 757 039 |
|
465 000 |
|
5 222 039 |
|
USD |
|
22.77 |
|
110.0 |
|
116.3 |
|
Relay Therapeutics |
|
1 409 357 |
|
1 211 605 |
|
2 620 962 |
|
USD |
|
36.59 |
|
88.7 |
|
51.8 |
|
Esperion Therapeutics |
|
3 947 964 |
|
530 000 |
|
4 477 964 |
|
USD |
|
21.15 |
|
87.6 |
|
90.9 |
|
Beam Therapeutics |
|
396 821 |
|
210 000 |
|
606 821 |
|
USD |
|
128.71 |
|
72.2 |
|
28.7 |
|
Molecular Templates |
|
6 380 331 |
|
3 162 290 |
|
9 542 621 |
|
USD |
|
7.82 |
|
69.0 |
|
53.0 |
|
Essa Pharma |
|
– |
|
2 440 814 |
|
2 440 814 |
|
USD |
|
28.57 |
|
64.5 |
|
– |
|
Generation Bio Co. |
|
2 333 180 |
|
120 000 |
|
2 453 180 |
|
USD |
|
26.90 |
|
61.0 |
|
58.6 |
|
Scholar Rock Holding |
|
2 255 651 |
|
19 474 |
|
2 275 125 |
|
USD |
|
28.90 |
|
60.8 |
|
96.9 |
|
Halozyme Therapeutics |
|
3 970 000 |
|
(2 638 034) |
|
1 331 966 |
|
USD |
|
45.41 |
|
55.9 |
|
150.1 |
|
Revolution Medicines |
|
– |
|
1 805 105 |
|
1 805 105 |
|
USD |
|
31.74 |
|
53.0 |
|
– |
|
Exelixis |
|
2 835 000 |
|
– |
|
2 835 000 |
|
USD |
|
18.22 |
|
47.8 |
|
50.4 |
|
Nektar Therapeutics |
|
2 620 676 |
|
– |
|
2 620 676 |
|
USD |
|
17.16 |
|
41.6 |
|
39.4 |
|
Black Diamond Therapeutics |
|
1 390 000 |
|
2 050 000 |
|
3 440 000 |
|
USD |
|
12.19 |
|
38.8 |
|
39.4 |
|
Mersana Therapeutics |
|
1 885 000 |
|
975 000 |
|
2 860 000 |
|
USD |
|
13.58 |
|
35.9 |
|
44.4 |
|
Kezar Life Sciences |
|
4 533 148 |
|
– |
|
4 533 148 |
|
USD |
|
5.43 |
|
22.8 |
|
20.9 |
|
Wave Life Sciences |
|
2 602 858 |
|
– |
|
2 602 858 |
|
USD |
|
6.66 |
|
16.0 |
|
18.1 |
|
Homology Medicines |
|
1 737 122 |
|
– |
|
1 737 122 |
|
USD |
|
7.27 |
|
11.7 |
|
17.4 |
|
Alexion Pharmaceuticals |
|
1 294 428 |
|
(1 294 428) |
|
– |
|
USD |
|
n.a |
|
– |
|
179.0 |
|
Voyager Therapeutics |
|
2 680 283 |
|
(2 680 283) |
|
– |
|
USD |
|
n.a |
|
– |
|
17.0 |
|
Cidara Therapeutics |
|
2 822 495 |
|
(2 822 495) |
|
– |
|
USD |
|
n.a |
|
– |
|
5.0 |
|
Total shares |
|
|
|
|
|
|
|
|
|
|
|
4 347.0 |
|
3 952.5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Alder Biopharmaceuticals – Contingent Value Right |
|
2 766 008 |
|
– |
|
2 766 008 |
|
USD |
|
0.88 |
|
2.3 |
|
2.2 |
|
Bristol-Myers Squibb – Contingent Value Right |
|
800 000 |
|
(800 000) |
|
– |
|
USD |
|
n.a |
|
– |
|
– |
|
Total derivative instruments |
|
|
|
|
|
|
|
|
|
|
|
2.3 |
|
2.2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total securities |
|
|
|
|
|
|
|
|
|
|
|
4 349.3 |
|
3 954.7 |
The changes in value of securities at fair value through profit or loss by investment category are as follows (in CHF 1 000):
|
|
|
Listed shares |
|
Unlisted shares |
|
Derivative instruments |
|
Total |
|
Opening balance as at 01.01.2020 at fair values |
|
3 518 985 |
|
– |
|
4 685 |
|
3 523 670 |
|
Purchases |
|
699 570 |
|
– |
|
– |
|
699 570 |
|
Sales |
|
(1 010 092) |
|
– |
|
– |
|
(1 010 092) |
|
Net gains/(losses) from securities |
|
744 042 |
|
– |
|
(2 531) |
|
741 511 |
|
Realized gains |
|
364 618 |
|
– |
|
– |
|
364 618 |
|
Realized losses |
|
(83 963) |
|
– |
|
– |
|
(83 963) |
|
Unrealized gains |
|
882 536 |
|
– |
|
– |
|
882 536 |
|
Unrealized losses |
|
(419 149) |
|
– |
|
(2 531) |
|
(421 680) |
|
Closing balance as at 31.12.2020 at fair values |
|
3 952 504 |
|
– |
|
2 155 |
|
3 954 659 |
|
|
|
|
|
|
|
|
|
|
|
Opening balance as at 01.01.2021 at fair values |
|
3 952 504 |
|
– |
|
2 155 |
|
3 954 659 |
|
Purchases |
|
556 774 |
|
– |
|
– |
|
556 774 |
|
Sales |
|
(541 981) |
|
– |
|
– |
|
(541 981) |
|
Net gains/(losses) from securities |
|
379 717 |
|
– |
|
97 |
|
379 813 |
|
Realized gains |
|
90 572 |
|
– |
|
– |
|
90 572 |
|
Realized losses |
|
(1 530) |
|
– |
|
(2 330) |
|
(3 860) |
|
Unrealized gains |
|
625 304 |
|
– |
|
97 |
|
625 401 |
|
Unrealized losses |
|
(334 629) |
|
– |
|
2 330 |
|
(332 299) |
|
Closing balance as at 30.06.2021 at fair values |
|
4 347 013 |
|
– |
|
2 252 |
|
4 349 265 |